Chloroquine as a Modulator of T Cell Immune Activation
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of chloroquine in individuals infected with HIV.
Researchers will aim to determine if chloroquine treatment in participants whose viral loads
are suppressed on combination antiretroviral therapy (ART), results in improved immune
activation and CD4 cell recovery.
The study will recruit 20 individuals and will last approximately 44 weeks. Eligible
participants will receive an oral dose of chloroquine (250 mg) once daily from week 8 through
week 32. All participants will be asked to have rectal biopsy samples (week 0 and week 32) to
study T cell immune activation in the mucosa rectal site.